Vertex Pharmaceuticals Inc
VRTX387.150USD
-4.210-1.08%
Close 09/17, 16:00（ET）Quotes delayed by 15 min
99.22BMarket Cap
27.28P/E TTM
More Details of Vertex Pharmaceuticals Inc Company
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Company Info
Ticker SymbolVRTX
Company nameVertex Pharmaceuticals Inc
IPO dateJul 24, 1991
CEODr. Reshma Kewalramani
Number of employees6100
Security typeOrdinary Share
Fiscal year-endJul 24
Address50 Northern Avenue
CityBOSTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02210
Phone16173416393
Websitehttps://www.vrtx.com/
Ticker SymbolVRTX
IPO dateJul 24, 1991
CEODr. Reshma Kewalramani
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-5.51%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
By RegionUSD
Name
Revenue
Proportion
United States
1.65B
59.91%
Europe
826.60M
29.95%
Other
280.10M
10.15%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
11.21%
The Vanguard Group, Inc.
9.31%
Capital Research Global Investors
6.28%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Global Advisors (US)
4.59%
Other
63.09%
Shareholders
Shareholders
Proportion
Capital World Investors
11.21%
The Vanguard Group, Inc.
9.31%
Capital Research Global Investors
6.28%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Global Advisors (US)
4.59%
Other
63.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
60.29%
Investment Advisor/Hedge Fund
28.71%
Research Firm
2.55%
Pension Fund
2.27%
Bank and Trust
1.99%
Sovereign Wealth Fund
1.49%
Hedge Fund
0.69%
Individual Investor
0.14%
Insurance Company
0.09%
Other
1.76%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
28.53M
11.11%
+207.61K
+0.73%
Mar 31, 2025
The Vanguard Group, Inc.
23.38M
9.1%
+232.41K
+1.00%
Mar 31, 2025
Capital Research Global Investors
14.54M
5.66%
+4.11M
+39.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.00M
5.45%
-330.35K
-2.31%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.59%
-190.75K
-1.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
2.97%
-1.49M
-16.32%
Mar 31, 2025
Jennison Associates LLC
5.06M
1.97%
+744.68K
+17.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.76M
2.24%
+113.52K
+2.01%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
5.31M
2.07%
-20.76K
-0.39%
Jun 30, 2025
Wellington Management Company, LLP
5.45M
2.12%
-461.34K
-7.80%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
VanEck Biotech ETF
10.62%
iShares Biotechnology ETF
6.92%
First Trust NYSE Arca Biotechnology Index Fund
3.35%
SPDR S&P Biotech ETF
2.44%
iShares U.S. Healthcare ETF
2.39%
Health Care Select Sector SPDR Fund
2.34%
Fidelity MSCI Health Care Index ETF
2.06%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
1.81%
Capital Group Core Equity ETF
1.77%
iShares Global Healthcare ETF
1.68%
View more
VanEck Biotech ETF
Proportion10.62%
iShares Biotechnology ETF
Proportion6.92%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.35%
SPDR S&P Biotech ETF
Proportion2.44%
iShares U.S. Healthcare ETF
Proportion2.39%
Health Care Select Sector SPDR Fund
Proportion2.34%
Fidelity MSCI Health Care Index ETF
Proportion2.06%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
Proportion1.81%
Capital Group Core Equity ETF
Proportion1.77%
iShares Global Healthcare ETF
Proportion1.68%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
